Product approval information is indicated for treatment of chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha-1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/zJ8d0aU
No comments:
Post a Comment